Abstract

Major Study Affirming the Relative Safety of Testosterone-replacement Therapy

Author(s): Biundo Bruce

Issue: Sep/Oct 2023 - Volume 27, Number 5

Page(s): 358-360

Download in electronic PDF format for $75
  • Major Study Affirming the Relative Safety of Testosterone-replacement Therapy Page 1
  • Major Study Affirming the Relative Safety of Testosterone-replacement Therapy Page 2
  • Major Study Affirming the Relative Safety of Testosterone-replacement Therapy Page 3

Abstract

Between warnings from the U.S. Food and Drug Administration and many articles being published with the consensus that testosterone-replacement therapy had an increased cardiovascular risks in men, thereby questioning the relative safety of the therapy, the needs of hypogonadal (low testosterone) men, who also present with symptoms related to this condition, are much less likely to receive a treatment that can significantly improve their quality of life. This article discusses a major research project that determined that testosterone replacement therapy was no worse than a placebo in men with cardiovascular disease or at high risk for cardiovascular disease.

Related Keywords

  • testosterone replacement
  • androgenic hormone
  • hypogonadism
  • men
  • drug safety
  • cardiovascular health
  • U.S. Food and Drug Administration
  • FDA
  • black box warning
  • adverse effects
  • clinical trials
  • TRAVERSE trial
  • cardiovascular disease risk

Related Categories

  • HRT
  • ADVERSE DRUG EVENTS
  • CARDIOLOGY
  • ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Sep/Oct 2023
Pg. 358-360
Major Study Affirming the Relative Safety of Testosterone-replacement Therapy
Author(s): Biundo Bruce
Nov/Dec 2020
Pg. 451-458
Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety
Author(s): Allen W Chris, Greeson Nicole MH, Mixon William
Sep/Oct 2017
Pg. 356
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Author(s): Allen Loyd V Jr
May/Jun 2006
Pg. 175-183
The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States
Author(s): Stephenson Kenna, Jones William, Stephenson Douglas M M
Jul/Aug 2011
Pg. 290-300
Impact of Conventional and Bioidentical Hormone Replacement Therapy on Cardiovascular and Breast Health: A Review
Author(s): Ruiz Andres D, Daniels Kelly R, Barner Jamie C, Carson John J, Frei Christopher R
Jul/Aug 2020
Pg. 270-276
Safety Standards in Pharmaceutical Compounding, Part 1: The Occupational Safety and Health Administration
Author(s): Greeson Nicole MH, Mixon William, Allan W Chris
Jul/Aug 2016
Pg. 351
View Sample
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Author(s): Allen Loyd V Jr
Sep/Oct 2016
Pg. 359-364
Menopausal Symptom Relief and Side Effects Experienced by Women Using Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 1
Author(s): Deleruyelle Laura J
Jan/Feb 2015
Pg. 6-12
Efficacy and Clinical Value of Commonly Compounded Hormone Replacement Therapy: A Literature Review
Author(s): Beshay Sarah M, Rivera Gerard, Balthasar Jan, Florea Naomi
Jan/Feb 2013
Pg. 74-85
View Sample
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women
Author(s): Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K
Jul/Aug 2015
Pg. 303-305
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Author(s): Miller David G
Jan/Feb 2001
Pg. 52-54
Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens - Part 2
Author(s): Ford Gina, Garcia Lea
Nov/Dec 2015
Pg. 487-488
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Author(s): Allen Loyd V Jr
Jul/Aug 2020
Pg. 296-297
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Author(s): Brunner Scott
Jul/Aug 2019
Pg. 325-339
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy
Author(s): Glaser Rebecca L, York Anne E
Jan/Feb 2023
Pg. 22-23
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone
Author(s): Brunner Scott
Jul/Aug 2005
Pg. 259-264
View Sample
Testosterone Replacement Therapy for Female Androgen Insufficiency Syndrome
Author(s): Tan Robert S
Jul/Aug 2003
Pg. 250-256
A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 1
Author(s): Gillson George R, Zava David T
Nov/Dec 2016
Pg. 447-454
Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 2
Author(s): Deleruyelle Laura J
May/Jun 2013
Pg. 182-190
Complying with Occupational Safety and Health Administration Regulations: A Guide for Compounding Pharmacists
Author(s): Mixon Bill, Nain John